DESTINA GENOMICS

destina-genomics-logo

DestiNA Genomics Ltd (DGL) is a University of Edinburgh spin-out company, formed to commercialise a revolutionary chemical based system for detecting nucleic acids and single nucleotide polymorphisms (SNPโ€™s). DGL has entered into an exclusive Licence Agreement with the University of Edinburgh, covering the development and commercialisation arising from the patent โ€œNucleobase Characterisationโ€. The technology is unique and distinguishable from ALL existing enzymatic methods of nucleic acid ... analysis. DGL intends to develop and launch a completely โ€˜PCR freeโ€™ system for nucleic acid analysis, using the unique properties of the nucleobase chemistry. In particular, DGL has identified that its reagents are particularly suited for direct detection of micro-RNAโ€™s.DestiNA is working with trade partners to integrate their technology within colorimetric, fluorescent and electrochemical-based detection platforms. DestiNA Genomics Ltd has incorporated a Spanish company called DestiNA Genomica SL with the goal of exploit our technology in Spain with different partners such as Master Diagnostica. DestiNA Genomica SL. was awarded a grant from the Technological Fund of Invest in Spain (1-2011/55 โ‚ฌ239,000). The Technological Fund of Invest in Spain is a special area of ERDF funds from the European Union created to promote business R&D&I in Spain for the 2007-2013 period.

#SimilarOrganizations #People #Financial #Website #More

DESTINA GENOMICS

Social Links:

Industry:
Biotechnology Genetics

Founded:
2010-01-01

Address:
Edinburgh, Edinburgh, City Of, United Kingdom

Country:
United Kingdom

Website Url:
http://www.destinagenomics.com

Total Employee:
11+

Status:
Active

Contact:
+44 (0)162 082 2611

Email Addresses:
[email protected]

Total Funding:
1.2 M EUR

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics


Similar Organizations

voyager-therapeutics-logo

Voyager Therapeutics

Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.

Current Employees Featured

hugh-ilyine_image

Hugh Ilyine
Hugh Ilyine Chief Executive Officer @ DestiNA Genomics
Chief Executive Officer
2010-11-01

juan-j-diaz-mochon_image

Juan J. Diaz Mochon
Juan J. Diaz Mochon Founder & CSO @ DestiNA Genomics
Founder & CSO
2010-09-01

Founder


juan-j-diaz-mochon_image

Juan J. Diaz Mochon

Investors List

vitro-group_image

Vitro Group

Vitro Group investment in Seed Round - DestiNA Genomics

scottish-investment-bank_image

Scottish Investment Bank

Scottish Investment Bank investment in Seed Round - DestiNA Genomics

old-college-capital_image

Old College Capital

Old College Capital investment in Seed Round - DestiNA Genomics

Official Site Inspections

http://www.destinagenomics.com

  • Host name: 217-160-0-183.elastic-ssl.ui-r.com
  • IP address: 217.160.0.183
  • Location: Germany
  • Latitude: 51.2993
  • Longitude: 9.491
  • Timezone: Europe/Berlin

Loading ...

More informations about "DestiNA Genomics"

About Us - DESTINA

[email protected]. DESTINA Genomics Ltd. 7-11 Melville St, Edinburgh EH3 7PE, United Kingdom. +44 (0) 162 082 2611 [email protected]; RECENT POSTS. โ€ฆSee details»

DestiNA Genomics - Crunchbase Company Profile

Contact Email [email protected] Phone Number +44 (0)162 082 2611 DestiNA Genomics Ltd (DGL) is a University of Edinburgh spin-out company, formed to commercialise a revolutionary chemical based system for detecting โ€ฆSee details»

Contact - DESTINA

[email protected]. DESTINA Genomics Ltd. 7-11 Melville St, Edinburgh EH3 7PE, United Kingdom. +44 (0) 162 082 2611 [email protected]; RECENT POSTS. โ€ฆSee details»

DESTINA Genomics Ltd. Management Team | Org Chart

DESTINA Genomics Ltd. is a biotech company founded in Edinburgh in 2011 by Hugh Ilyine, Juan J. Diaz-Mochon and Mark Bradley. In July 2012, it was created the Spanish subsidiary โ€ฆSee details»

DESTINA Genomics Company Profile | Management and โ€ฆ

[email protected]: DESTINA Genomics Top Competitors. Company Employees Revenue Top technologies; BioStatus. 7: $1.5 M: Diagast. n/a: $16.8 M: Eurobio. n/a: $6.6 M: โ€ฆSee details»

DestiNA Genomics Ltd - VentureRadar

Title: A novel platform for the direct profiling of circulating cell-free ribonucleic acids in biofluids (Acronym: diaRNAgnosis) | Total Cost: โ‚ฌ759000 / EU contribution: โ‚ฌ759000 | Start: 2021-01 โ€ฆSee details»

DestiNA Genomics - Company Profile - Tracxn

4 days ago DestiNA Genomics - Develops non-enzymatic nucleic acid detection technology. Raised funding over 3 rounds from 2 investors. Valued at $4.29M. Founded by Hugh Ilyine โ€ฆSee details»

DestiNA Genomics Ltd - VentureRadar

DestiNA Genomics Ltd (DGL) was founded in April 2010 by Hugh Ilyine, Juan J. Diaz-Mochon and Mark Bradley as a start-up from Edinburgh University,... ... Find out ...See details»

Destina Genomics - Craft

Destina Genomics has 5 employees across 2 locations and $1.51 m in total funding,. See insights on Destina Genomics including office locations, competitors, revenue, financials, executives, โ€ฆSee details»

DESTINA Genomics Ltd. - Company Profile & Staff Directory

DESTINA Genomics Ltd. is a biotech company founded in Edinburgh in 2011 by Hugh Ilyine, Juan J. Diaz-Mochon and Mark Bradley. In July 2012, it was created the Spanish subsidiary โ€ฆSee details»

People - DESTINA

Oct 9, 2023 [email protected]. DESTINA Genomics Ltd. 7-11 Melville St, Edinburgh EH3 7PE, United Kingdom. +44 (0) 162 082 2611 [email protected]; RECENT โ€ฆSee details»

Destina Genomics Ltd.: Drug pipelines, Patents, Clinical trials

Jun 17, 2023 Explore Destina Genomics Ltd. with its drug pipeline, therapeutic area, technology platform, 1 literature.See details»

DestiNA Genomics - Products, Competitors, Financials, Employees ...

Destina Genomics, Mecwins to Jointly Develop RNA Biomarker Tests. Oct 13, 2021. Save for later NEW YORK โ€“ Destina Genomics and Mecwins have entered into a cross-licensing โ€ฆSee details»

DESTINA Company Profile 2024: Valuation, Funding & Investors

DESTINA General Information Description. Developer of molecular diagnostic products designed to detect nucleic acids and single nucleotide polymorphisms (SNPs). The company's product โ€ฆSee details»

DestiNA Genomics raises โ‚ฌ1,200,000 to develop novel tests for โ€ฆ

[email protected]. HBJ Gateley contact: Bryan Garvie, The BIG Partnership. 0141 333 9585 / 07863 208045. About DestiNA Genomics Ltd: DestiNA Genomics Ltd is a University of โ€ฆSee details»

Redesigned DESTINA website goes... - DESTINA Genomics Ltd

Redesigned DESTINA website goes live February 25th 2020 Biotech innovator DESTINA Genomics has a new redesigned and upgraded website at www.destinagenomics.com Now โ€ฆSee details»

Products & Services - DESTINA

[email protected]. DESTINA Genomics Ltd. 7-11 Melville St, Edinburgh EH3 7PE, United Kingdom. +44 (0) 162 082 2611 [email protected]; RECENT POSTS. โ€ฆSee details»

Products - DESTINA

[email protected]. DESTINA Genomics Ltd. 7-11 Melville St, Edinburgh EH3 7PE, United Kingdom. +44 (0) 162 082 2611 [email protected]; RECENT POSTS. โ€ฆSee details»

Technology - DESTINA

[email protected]. DESTINA Genomics Ltd. 7-11 Melville St, Edinburgh EH3 7PE, United Kingdom. +44 (0) 162 082 2611 [email protected]; RECENT POSTS. โ€ฆSee details»

linkstock.net © 2022. All rights reserved